Abstract
BackgroundBurosumab, an antifibroblast growth factor 23 monoclonal antibody, improves rickets severity, symptoms and growth in children with X-linked hypophosphataemia (XLH) followed up to 64 weeks in clinical trials. International dosing...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have